MoneyWorks4Me

Cipla informs about update

04 Aug 2026 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to its intimation dated 10th February, 2026 regarding the Pre-Approval Inspection (PAI) conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals, Inc. (‘InvaGen’), a wholly-owned subsidiary of the Company, located in Hauppauge, Long Island, New York, USA, Cipla has informed that InvaGen has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection.

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1472.00 -3.00 (-0.20%)
07-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1949.00
Dr. Reddys Labs. 1172.00
Cipla 1472.00
Lupin 2360.00
Zydus Lifesciences 1115.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: